The trial aims to investigate the safety, tolerability and antiviral activity of INX-189 in conjunction with pegylated interferon and ribavirin in chronic HCV-infected genotype 2 and 3 treatment naive patients.
The trial is intended to assess three once-daily doses of INX-189 (25 mg, 50 mg and 100 mg) administered in combination with pegylated interferon and ribavirin for 12 weeks.